Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06829173 · ClinicalTrials.gov registry record · Early Phase 1
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
A Early Phase 1 study of High Grade Glioma, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06829173 is a Early Phase 1 study of High Grade Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 39 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06829173, a Early Phase 1 study of High Grade Glioma, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.
Conditions Studied
Interventions
- PROCEDURE Surgical Resection
- RADIATION Radiation Therapy
- DRUG XRD-0394
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2031-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06829173
The ClinicalTrials.gov registry entry for NCT06829173 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (40% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 3 interventions - of which Surgical Resection is the first listed.
NCT06829173 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06829173 about?
NCT06829173 is a clinical study titled "Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas". This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gli...
What is the current status of trial NCT06829173?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2025-11-05. Estimated completion is 2031-05.
What conditions does trial NCT06829173 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT06829173?
The interventions under investigation include: Surgical Resection (PROCEDURE), Radiation Therapy (RADIATION), XRD-0394 (DRUG).
Who is sponsoring clinical trial NCT06829173?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06829173 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
RECRUITING · Early Phase 1
-
18F-Fluciclovine PET-MRI in High-grade Glioma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.